Identification

Name
Isosorbide dinitrate
Accession Number
DB00883  (APRD00455)
Type
Small Molecule
Groups
Approved, Investigational
Description

A vasodilator used in the treatment of angina pectoris. Its actions are similar to nitroglycerin but with a slower onset of action.

Structure
Thumb
Synonyms
  • 1,4:3,6-Dianhydrosorbitol 2,5-dinitrate
  • D-Isosorbide dinitrate
  • Dianhydrosorbitol 2,5-dinitrate
  • Dinitrate d'isosorbide
  • Dinitrate dʼisosorbide
  • Dinitrato de isosorbida
  • Dinitroisosorbide
  • Dinitrosorbide
  • ISDN
  • Isosorbide 2,5-dinitrate
  • Isosorbidi dinitras
  • Sorbide nitrate
  • Sorbidnitrate
External IDs
C01DA08
Active Moieties
NameKindUNIICASInChI Key
IsosorbideunknownWXR179L51S652-67-5KLDXJTOLSGUMSJ-JGWLITMVSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cedocard-SR Srt 20mgTablet, extended release20 mgOralPaladin Labs Inc1987-12-312009-08-07Canada
Cedocard-SR Srt 40mgTablet, extended release40 mgOralPaladin Labs Inc1995-12-312009-08-07Canada
Coradur Tab 20mgTablet, extended release20 mgOralGlaxo Canada Inc1987-12-311997-04-25Canada
CoronexTablet30 mgOralWyeth Ltd.1994-12-312007-01-08Canada
CoronexTablet10 mgOralWyeth Ltd.1994-12-312007-01-08Canada
Coronex 5mg Sublingual TabletsTablet5 mgSublingualWyeth Ltd.1994-12-312007-01-08Canada
Dilatrate SRCapsule, extended release40 mg/1OralEndo Pharmaceuticals2012-02-15Not applicableUs
Dilatrate SRCapsule40 mg/1OralAuxilium Pharmaceuticals, Inc.2014-10-242015-10-15Us
IsdnTablet10 mgOralAa Pharma Inc1982-12-31Not applicableCanada
IsdnTablet5 mgSublingualAa Pharma Inc1985-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
IsoDitrateTablet, extended release40 mg/1OralAmedra Pharmaceuticals2010-04-302010-04-30Us
IsosorbideTablet20 mg/1OralMed Health Pharma LLC.2011-03-022012-04-15Us
IsosorbideTablet20 mg/1OralGolden State Medical Supply1987-11-02Not applicableUs
IsosorbideTablet10 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs53808 027420180907 15195 14vkirl
IsosorbideTablet20 mg/1OralMc Kesson Contract Packaging2011-11-042017-09-30Us
IsosorbideTablet10 mg/1OralHikma Pharmaceutical1978-12-01Not applicableUs
IsosorbideTablet10 mg/1OralMed Health Pharma LLC.2011-03-022012-04-15Us
IsosorbideTablet10 mg/1OralGolden State Medical Supply1987-10-26Not applicableUs00143 1771 10 nlmimage10 71083881
IsosorbideTablet20 mg/1OralCardinal Health1987-10-292012-10-31Us
IsosorbideTablet10 mg/1OralMc Kesson Contract Packaging1978-12-012017-09-30Us
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
BiDilIsosorbide dinitrate (20 mg/1) + Hydralazine hydrochloride (37.5 mg/1)Tablet, film coatedOralArbor Pharmaceuticals2012-12-05Not applicableUs24338 01020180907 15195 ecm0g8
BiDilIsosorbide dinitrate (20 mg/1) + Hydralazine hydrochloride (37.5 mg/1)Tablet, film coatedOralArbor Pharmaceuticals2005-06-232015-12-31Us12948 0001 12 nlmimage10 2f131798
BiDilIsosorbide dinitrate (20 mg/1) + Hydralazine hydrochloride (37.5 mg/1)Tablet, film coatedOralRemedy Repack2013-10-082013-10-09Us
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Dilatrate-SRIsosorbide dinitrate (40 mg/1)Capsule, extended releaseOralSchwarz Pharma2008-01-23Not applicableUs0091 092020180818 17235 br9l0e
Isorbide DinitrateIsosorbide dinitrate (40 mg/1)Tablet, extended releaseOralInwood Laboratories, Inc.2006-10-08Not applicableUs
IsordilIsosorbide dinitrate (5 mg/1)TabletOralUNSPECIFIED2006-03-202006-03-20Us
International/Other Brands
Carvasin (Ayerst) / Cedocard retard / Dilatrate-SR (Schwarz) / Flindix (Vitória) / Isoket (Schwarz) / Isorbid (Armstrong) / Isordil (Valeant) / Nitrosorbide (Lusofarmaco) / Sorbidilat (Actavis)
Categories
UNII
IA7306519N
CAS number
87-33-2
Weight
Average: 236.1363
Monoisotopic: 236.028065242
Chemical Formula
C6H8N2O8
InChI Key
MOYKHGMNXAOIAT-JGWLITMVSA-N
InChI
InChI=1S/C6H8N2O8/c9-7(10)15-3-1-13-6-4(16-8(11)12)2-14-5(3)6/h3-6H,1-2H2/t3-,4+,5-,6-/m1/s1
IUPAC Name
(3R,3aS,6S,6aS)-6-(nitrooxy)-hexahydrofuro[3,2-b]furan-3-yl nitrate
SMILES
[H][C@]12OC[C@H](O[N+]([O-])=O)[C@@]1([H])OC[C@H]2O[N+]([O-])=O

Pharmacology

Indication

For the prevention of angina pectoris due to coronary artery disease.

Associated Conditions
Pharmacodynamics

Isosorbide Dinitrate is a moderate to long acting oral organic nitrate used for the relief and prophylactic management of angina pectoris. It relaxes the vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to the heart, thereby reducing left ventricular end- diastolic pressure and pulmonary capillary wedge pressure (preload). Arteriolar relaxation reduces systemic vascular resistance, systolic arterial pressure, and mean arterial pressure.

Mechanism of action

Similar to other nitrites and organic nitrates, isosorbide dinitrate is converted to nitric oxide (NO), an active intermediate compound which activates the enzyme guanylate cyclase (atrial natriuretic peptide receptor A). This stimulates the synthesis of cyclic guanosine 3',5'-monophosphate (cGMP) which then activates a series of protein kinase-dependent phosphorylations in the smooth muscle cells, eventually resulting in the dephosphorylation of the myosin light chain of the smooth muscle fiber. The subsequent release of calcium ions results in the relaxation of the smooth muscle cells and vasodilation.

TargetActionsOrganism
AAtrial natriuretic peptide receptor 1
agonist
Human
Absorption

Absorption of isosorbide dinitrate after oral dosing is nearly complete, but bioavailability is highly variable (10% to 90%), with extensive first-pass metabolism in the liver. The average bioavailability of isosorbide dinitrate is about 25%.

Volume of distribution
  • 2 to 4 L/kg
Protein binding

Very low

Metabolism

Hepatic

Route of elimination
Not Available
Half life

1 hour

Clearance
Not Available
Toxicity

Symptoms of overdose include reduced cardiac output and hypotension.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AcebutololThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Acebutolol.
AlbendazoleThe metabolism of Isosorbide dinitrate can be decreased when combined with Albendazole.
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Isosorbide dinitrate.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Isosorbide Dinitrate.
AlfuzosinThe metabolism of Isosorbide dinitrate can be decreased when combined with Alfuzosin.
AliskirenThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Aliskiren.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Isosorbide dinitrate.
AmcinonideThe metabolism of Amcinonide can be decreased when combined with Isosorbide dinitrate.
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Isosorbide Dinitrate.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Isosorbide Dinitrate.
Food Interactions
  • Take without regard to meals. Absorption is faster on an empty stomach.

References

Synthesis Reference

Gunter Cordes, Ulrich Munch, Ewald Giesselmann, "Supersaturated isosorbide dinitrate solution, process for its production and its use." U.S. Patent US4156736, issued August, 1976.

US4156736
General References
Not Available
External Links
Human Metabolome Database
HMDB0015021
KEGG Drug
D00516
KEGG Compound
C07456
PubChem Compound
6883
PubChem Substance
46506412
ChemSpider
6619
ChEBI
6061
ChEMBL
CHEMBL6622
Therapeutic Targets Database
DAP001057
PharmGKB
PA450125
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Isosorbide_dinitrate
ATC Codes
C01DA58 — Isosorbide dinitrate, combinationsC05AE02 — Isosorbide dinitrateC01DA08 — Isosorbide dinitrate
AHFS Codes
  • 24:12.08 — Nitrates and Nitrites

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentDuchenne's Muscular Dystrophy (DMD)1
1CompletedTreatmentHeart Failure, Unspecified1
1, 2Active Not RecruitingTreatmentChronic Orthostatic Intolerance / Tachycardia1
2Active Not RecruitingTreatmentCongestive Heart Failure (CHF) / Heart Failure, Unspecified1
3Active Not RecruitingTreatmentAcute Heart Failure (AHF) / Symptomatic left ventricular ejection fraction ≤ 35% Chronic heart failure1
3CompletedTreatmentCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Ischemia1
3CompletedTreatmentDiabetic Foot Ulcers (DFU)1
3CompletedTreatmentHeart Failure, Unspecified / High Blood Pressure (Hypertension)1
3Unknown StatusTreatmentCardio-Renal Syndrome1
4CompletedBasic SciencePost-anesthesia Recovery1
4CompletedPreventionAdverse Effects / Coronary Artery Atherosclerosis / Insulin resistance syndrome1
4CompletedTreatmentCongestive Heart Failure (CHF)1
4CompletedTreatmentCoronary Artery Stenosis / Coronary Heart Disease (CHD)1
4CompletedTreatmentMaternal Care for Late Fetal Death / Pregnancy, Cornual1
4CompletedTreatmentMyocardial Ischemia / Quality of Life / Stable Angina (SA)1
4RecruitingPreventionChronic Hemodialysis (ESRD)1
4RecruitingTreatmentDiabetes Mellitus (DM) / Heart Failure, Unspecified1
Not AvailableActive Not RecruitingPreventionCardio-Renal Syndrome1
Not AvailableCompletedHealth Services ResearchBMI >30 kg/m21
Not AvailableNot Yet RecruitingTreatmentHeart Decompensation1
Not AvailableRecruitingNot AvailableHeart Failure, Unspecified1
Not AvailableRecruitingPreventionPancreatitis1
Not AvailableRecruitingTreatmentAcute Coronary Syndromes (ACS)1
Not AvailableUnknown StatusBasic ScienceCoronary Artery Disease1

Pharmacoeconomics

Manufacturers
  • Alcon laboratories inc
  • Schwarz pharma inc
  • Wyeth ayerst laboratories
  • Astrazeneca pharmaceuticals lp
  • Caraco pharmaceutical laboratories ltd
  • Corepharma llc
  • Biovail laboratories inc
  • Mutual pharmaceutical co inc
  • Par pharmaceutical inc
  • Sandoz inc
  • Superpharm corp
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • West ward inc
Packagers
  • Amedra Pharmaceuticals LLC
  • Amerisource Health Services Corp.
  • Atlantic Biologicals Corporation
  • Bryant Ranch Prepack
  • BTA Pharmaceuticals
  • Caraco Pharmaceutical Labs
  • Cardinal Health
  • Consolidated Midland Corp.
  • Corepharma LLC
  • Dept Health Central Pharmacy
  • DHHS Program Support Center Supply Service Center
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Eon Labs
  • Forest Pharmaceuticals
  • Golden State Medical Supply Inc.
  • H and H Laboratories
  • Heartland Repack Services LLC
  • Hikma Pharmaceuticals
  • Inwood Labs
  • Kaiser Foundation Hospital
  • Lake Erie Medical and Surgical Supply
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Meda AB
  • Murfreesboro Pharmaceutical Nursing Supply
  • Neighborcare Repackaging Inc.
  • Nitromed Inc.
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • Par Pharmaceuticals
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Qualitest
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Rising Pharmaceuticals
  • Sandhills Packaging Inc.
  • Sandoz
  • Schwarz Pharma Inc.
  • Southwood Pharmaceuticals
  • Talbert Medical Management Corp.
  • Tya Pharmaceuticals
  • Va Cmop Dallas
  • Vangard Labs Inc.
  • Watson Pharmaceuticals
  • West-Ward Pharmaceuticals
Dosage forms
FormRouteStrength
Tablet, film coatedOral
Tablet, extended releaseOral20 mg
Tablet, extended releaseOral40 mg
CapsuleOral40 mg/1
Capsule, extended releaseOral40 mg/1
TabletOral10 mg
TabletOral30 mg
TabletSublingual5 mg
Tablet, extended releaseOral40 mg/1
TabletOral2.5 mg/1
TabletOral40 mg/1
TabletOral10 mg/1
TabletOral20 mg/1
TabletOral30 mg/1
TabletOral5 mg/1
TabletSublingual2.5 mg/1
TabletSublingual5 mg/1
Prices
Unit descriptionCostUnit
Isordil Titradose 40 mg tablet1.7USD tablet
Isordil 40 mg tablet1.58USD tablet
Dilatrate-sr 40 mg capsule1.48USD capsule
Isochron 40 mg tablet sa1.07USD tablet
Isosorbide Dinitrate CR 40 mg Controlled Release Tabs0.88USD tab
Isosorbide Mononitrate 20 mg tablet0.78USD tablet
Isosorbide Mononitrate 10 mg tablet0.74USD tablet
Isordil Titradose 5 mg tablet0.68USD tablet
Isordil 5 mg tablet0.65USD tablet
Isosorbide dn 30 mg tablet0.53USD tablet
Isordil 10 mg tablet0.5USD tablet
Isosorbide Dinitrate 30 mg tablet0.5USD tablet
Cedocard-Sr 20 mg Sustained-Release Tablet0.44USD tablet
Isosorbide Dinitrate 10 mg tablet0.43USD tablet
Isosorbide Dinitrate 20 mg tablet0.43USD tablet
Isosorbide Dinitrate 2.5 mg Sublingual Tabs0.39USD tab
Isosorbide Dinitrate 5 mg Sublingual Tabs0.21USD tab
Isosorbide dn 2.5 mg tablet sl0.21USD tablet
Isosorbide dn 5 mg tablet sl0.21USD tablet
Isosorbide dn 20 mg tablet0.2USD tablet
Isosorbide Dinitrate 5 mg tablet0.17USD tablet
Isosorbide dn 10 mg tablet0.17USD tablet
Isosorbide dn 5 mg tablet0.17USD tablet
Apo-Isdn 30 mg Tablet0.09USD tablet
Apo-Isdn 5 mg Sublingual Tablet0.07USD tablet
Apo-Isdn 10 mg Tablet0.04USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6465463No2000-09-082020-09-08Us
US6784177No2000-09-082020-09-08Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)70 °CPhysProp
water solubility550 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.31HANSCH,C ET AL. (1995)
logS-2.63ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.938 mg/mLALOGPS
logP0.87ALOGPS
logP-0.0096ChemAxon
logS-2.4ALOGPS
pKa (Strongest Basic)-4.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area123.2 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity42.76 m3·mol-1ChemAxon
Polarizability18.15 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.935
Blood Brain Barrier+0.9559
Caco-2 permeable-0.5746
P-glycoprotein substrateNon-substrate0.8064
P-glycoprotein inhibitor INon-inhibitor0.6173
P-glycoprotein inhibitor IINon-inhibitor0.8911
Renal organic cation transporterNon-inhibitor0.8453
CYP450 2C9 substrateNon-substrate0.9057
CYP450 2D6 substrateNon-substrate0.9021
CYP450 3A4 substrateSubstrate0.5298
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9534
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9538
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.7116
BiodegradationReady biodegradable0.7633
Rat acute toxicity2.4849 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5057
hERG inhibition (predictor II)Non-inhibitor0.9381
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as isosorbides. These are organic polycyclic compounds containing an isosorbide(1,4-Dianhydrosorbitol) moiety, which consists of two -oxolan-3-ol rings.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Furofurans
Sub Class
Isosorbides
Direct Parent
Isosorbides
Alternative Parents
Tetrahydrofurans / Alkyl nitrates / Organic nitro compounds / Organic nitric acids and derivatives / Oxacyclic compounds / Dialkyl ethers / Organic oxides / Organic nitrogen compounds / Hydrocarbon derivatives
Substituents
Isosorbide / Organic nitrate / Tetrahydrofuran / Alkyl nitrate / Organic nitric acid or derivatives / Organic nitro compound / Dialkyl ether / Ether / Allyl-type 1,3-dipolar organic compound / Organic 1,3-dipolar compound
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
nitrate ester, glucitol derivative (CHEBI:6061)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein kinase activity
Specific Function
Receptor for the atrial natriuretic peptide NPPA/ANP and the brain natriuretic peptide NPPB/BNP which are potent vasoactive hormones playing a key role in cardiovascular homeostasis. Has guanylate ...
Gene Name
NPR1
Uniprot ID
P16066
Uniprot Name
Atrial natriuretic peptide receptor 1
Molecular Weight
118918.11 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Villarroya M, Lopez MG, de Pascual R, Garcia AG: Preclinical profile of PF9404C, a nitric oxide donor with beta receptor blocking properties. Cardiovasc Drug Rev. 2005 Summer;23(2):149-60. [PubMed:16007231]
  4. Takabuchi S, Hirota K, Nishi K, Oda S, Oda T, Shingu K, Takabayashi A, Adachi T, Semenza GL, Fukuda K: The inhibitory effect of sodium nitroprusside on HIF-1 activation is not dependent on nitric oxide-soluble guanylyl cyclase pathway. Biochem Biophys Res Commun. 2004 Nov 5;324(1):417-23. [PubMed:15465035]
  5. Beauregard C, Brandt PC, Chiou GC: Nitric oxide and cyclic GMP-mediated protein secretion from cultured lacrimal gland acinar cells. J Ocul Pharmacol Ther. 2002 Oct;18(5):429-43. [PubMed:12419094]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Vuppugalla R, Mehvar R: Selective effects of nitric oxide on the disposition of chlorzoxazone and dextromethorphan in isolated perfused rat livers. Drug Metab Dispos. 2006 Jul;34(7):1160-6. doi: 10.1124/dmd.105.009050. Epub 2006 Apr 18. [PubMed:16621933]

Drug created on June 13, 2005 07:24 / Updated on September 23, 2018 19:37